Streetbeat News

VNRX

VolitionRx Limited

https://www.volition.com

Industry

Medical - Diagnostics & Research

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

EF Hutton analyst Tim Moore has assumed coverage of VolitionRX with a Buy rating and set a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 3:08 pm

Benchmark analyst Bruce Jackson has reiterated a Hold rating on VolitionRX (AMEX:VNRX).

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:50 pm

VolitionRX (AMEX:VNRX) reported Q2 EPS of $(0.08), beating the $(0.09) estimate, but missed sales estimates with $395.80K against $480.00K. EPS improved by 42.86% YoY, and sales increased by 82.98% YoY.

Portfolio Pulse from totan@benzinga.com

August 14, 2024 | 8:22 pm

VolitionRx shares are trading lower following the announcement of a $21.5 million registered direct offering.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 1:12 pm

EF Hutton analyst Tim Moore has reiterated a Buy rating on VolitionRX (AMEX:VNRX) and maintained a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 12:33 pm

Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on VolitionRX (AMEX:VNRX) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 3:11 pm

VolitionRx shares are trading lower following the announcement of Q1 sales results that fell below expectations.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 6:04 pm

EF Hutton analyst Tim Moore has maintained a Buy rating on VolitionRX (AMEX:VNRX) with a price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 5:11 pm

VolitionRX reported Q1 2024 earnings with a GAAP EPS of $(0.10), beating estimates by 9.09% but missed sales estimates by 55.96%, reporting $171.535K against an expected $389.500K.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:57 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. VolitionRX, Palisade Bio, Kintara Therapeutics, Protagenic Therapeutics, BIMI Intl Medical, and NKGen Biotech were among the gainers, with increases ranging from 20.4% to 33.6%. Conversely, Abeona Therapeutics, Rezolute, Jaguar Health, Adlai Nortye, Sunshine Biopharma, and Portage Biotech saw declines between 12.49% and 52.3%.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.